SURI vs XPH
Simplify Propel Opportunities ETF against State Street SPDR S&P Pharmaceuticals ETF: cost, size, returns, what they hold and how much of it is the same.
Overlap by weight
7%
6 shared positions
Fee gap
221 bp
XPH is cheaper
1-year return gap
26.2 pts
XPH is ahead
Larger fund
XPH
$462M
Side by side
| SURI | XPH | |
|---|---|---|
| Fund | Simplify Propel Opportunities ETF | State Street SPDR S&P Pharmaceuticals ETF |
| Issuer | Simplify | State Street SPDR |
| Category | Small Cap Blend | Health Care |
| Expense ratio | 2.56% | 0.35% |
| Assets | $75M | $462M |
| Average daily dollar volume | $133K | $15M |
| Listed | Feb 7, 2023 | Jun 19, 2006 |
| FrenzyCap score | 8 | 70 |
| 1-month return | −10.7% | −4.9% |
| 3-month return | −4.1% | −3.3% |
| Year to date | +3.3% | +15.4% |
| 1-year return | +7.3% | +33.5% |
| 30-day volatility | 25.8% | 21.3% |
| Worst drawdown, 1 year | −17.9% | −15.1% |
| Trailing 12-month yield | 15.80% | 0.42% |
| Holdings | 39 | 62 |
| Top 10 weight | 155.1% | 22.7% |
| Look-through P/E | — | — |
| Holdings vs fair value | +23.3% | +18.3% |
| Holdings above 200-day average | 74% | 59% |
| Net flow, latest 3 reported months | −$2.6M thru Jun 2026 | +$47M thru Jun 2026 |
| 30-day implied volatility | — | 28.4% |
| Holdings as of | as of Jun 30, 2026SEC filing | as of Oct 8, 2026issuer data |
Returns are price returns and exclude distributions. Flows are each fund's own latest reported months and may not cover the same period.
Largest shared holdings
11% of SURI · 8% of XPH
Sector mix of the stock holdings
| Sector | SURI | XPH | Gap |
|---|---|---|---|
| Health Care | 51.6% | 99.2% | −47.6% |
| Energy | 40.0% | 0.0% | +40.0% |
| Technology | 0.8% | 0.8% | +0.1% |
| Industrials | 0.0% | 0.0% | +0.0% |
More: full overlap table · SURI holdings · XPH holdings
Fund data comes from each fund's SEC filings and issuer disclosures and is shown with the date it is as of. SEC portfolio and flow filings become public about 60 days after the period they cover. Nothing here is investment advice; see Terms.